The Roche Cooperative Oral Ganciclovir Study randomized HIV-and CMV-seropositive subjects to oral GCV 1 g three times daily or to placebo. CMV disease occurred over 12 months in 26% of placebo subjects and 14% of GCV subjects, a significant difference [5] .
Introduction
Cytomegalovirus (CMV) disease is a devastating opportunistic infection of advanced HIV infection, reducing both quality of life and survival [1] [2] [3] . Oral ganciclovir (GCV) has been recently shown to be effective for maintenance CMV disease therapy [4] . Could it play a role in preventing symptomatic CMV disease? Two clinical trials addressed this question but came to conflicting conclusions.
The Terry Beirn Community Program for Clinical Research on AIDS study (CPCRA 023) enrolled patients with either positive CMV serologies or cultures. After the Roche study was reported in September 1994, subjects were permitted to switch to open-label oral GCV. As a result, exposure to oral GCV was 9.3 months for those randomized to GCV, but 2.1 months for those randomized to placebo [6] . Based on the intent-to-treat analysis with follow-up through June 1995, there were insignificant differences between the groups for any confirmed CMV disease and for death. Censoring data collected after September 1994 produced similar results [7] . CMV can be detected by DNA polymerase chain reaction (PCR) in the blood of many patients prior to the development of disease symptoms [8] [9] [10] [11] [12] . Oral GCV has been shown to reduce CMV disease in both patients with detectable CMV by PCR and in those without [12] . These findings raise the question of whether screening for presymptomatic CMV disease can identify a population for which oral GCV is an effective prevention intervention [12] .
With the rapidly growing number of drugs that can be used in HIV treatment and prevention of complications, and the changes in the US health-care system, cost factors are becoming increasingly important. When resources are limited, cost-effectiveness analyses can help by calculating values of alternative health-care resources. We performed a cost-effectiveness analysis to determine the conditions under which oral GCV would be a reasonable intervention for the prevention of symptomatic CMV disease.
Methods
We studied hypothetical HIV-infected patients with CD4 cell counts ≤ 50 × 10 6 /l and with positive CMV serologies but with no symptoms of CMV disease. We compared no intervention with two prevention strategies: oral GCV 1 g three times daily for life unless adverse reactions cause termination of the preventive therapy; and plasma CMV PCR testing every 3 months with oral GCV prescribed for persons with positive tests. We calculated life expectancy, disease-free life expectancy, the number of symptomatic CMV disease cases per cohort of 1000 patients, and the cost to extend life by 1 year.
Model
In this study we used a Markov model ( Fig. 1 ). Markov models are decision analysis models that describe the movements of the members of a population through a set of health states in order to determine prognosis [13] . Each month patients with no CMV face the risk of developing asymptomatic CMV viremia, symptomatic CMV disease, death from any cause, or no change in CMV status. In the next month, patients with asymptomatic CMV risk developing symptomatic CMV disease, remaining asymptomatic, or dying from any cause. Patients with symptomatic CMV disease risk dying from any cause. Patients with no CMV illness face all risks each month. If oral GCV is prescribed for all patients, the risk of developing asymptomatic or symptomatic CMV is reduced. By contrast, with the strategy in which PCR testing is performed every 3 months, oral GCV is prescribed only for those who have detectable asymptomatic CMV viremia with the intent of diminishing the risk of subsequent symptomatic CMV disease. In any case, if oral GCV is taken, each month patients risk an adverse reaction to GCV causing termination of preventive therapy with no subsequent benefit.
Assumptions
We used the assumptions outlined in Table 1 . The probability of HIV-infected patients developing symptomatic CMV disease (0.0150 per month) was taken from two large cohort studies, the Zidovudine Epidemiology Study and the Multicenter AIDS Cohort Study [3, 14] .
Our model requires the comparison of survival of CMV-diseased patients to the survival of patients without CMV disease. Survival for CMV-diseased patients has improved in recent years [15] , as has the survival of HIV-infected patients without CMV disease. Prior to the availability of GCV, survival after diagnosis of CMV retinitis ranged from 1 to 6 months. Recently, survival has improved to 12-13 months under optimal therapy [15, 16] . A study of patients enrolled in the late 1980s found that those with CMV disease survived a median of 173 days; survival was not calculated among those without CMV disease but mortality was 73% of the mortality of CMV-diseased patients [3] . A more recent study found median survival to be 267 days among patients with CMV disease; survival amongst other HIV-infected patients in the same clinic ranged from 35 days for patients with non-Hodgkin's lymphoma to 680 days for patients with herpes zoster [17] . We assumed survival to be 267 days for patients with CMV disease and that it is 73% of the survival of HIVinfected patients who do not develop CMV disease.
The effectiveness of oral GCV in preventing symptomatic CMV disease and the rate of adverse reactions were taken from the two clinical trials described previously [5] [6] [7] . Oral GCV reduces the risk by 0-49%. Absolute neutropenia occurred in 16 and 25% of the patients in the two trials [5] [6] [7] . In the Roche study, 16% of subjects stopped oral GCV because of adverse reactions, 10% for withdrawal from the study, 5% for administrative problems, and 3% were lost from followup [5] . We assumed that adverse reactions severe enough to terminate preventive therapy occur at a rate of 2% per month.
The proportion of patients with CMV disease who have preceding positive PCR tests is 63% for blood testing and 75% for urine testing [11] . We assumed 70% and made the simplifying assumption that all these patients will develop symptomatic CMV disease if oral GCV preventive therapy is not taken. This latter assumption favours the PCR testing intervention over no prevention intervention. We assumed the specificity of the CMV PCR test is 100% for this population, a bias in favour of the PCR testing intervention.
We made the following cost assumptions. All costs are expressed in 1996 US dollars, the societal perspective was used for costs and savings, and a 5% annual discount rate was used to calculate cost-effectiveness ratios. Oral GCV costs US$ 39 per day (suggested retail plus dispensing cost) [18] . Adverse reactions severe enough to cause termination of the course of therapy require three doses of granulocyte colony-stimulating factor and administrative fees. Hospitalization for CMV disease averages 13.4 days and costs US$ 14 500 [19] . CMV maintenance therapy (US$ 2640 per month) involves oral or intravenous GCV or foscarnet and three home nursing visits per week. A CMV PCR test costs US$ 200, based on the charges for commercial PCR testing for other conditions.
Results
A cohort of 1000 patients with CD4 counts ≤ 50 × 10 6 /l and with positive CMV serologies can expect 134 cases of symptomatic CMV disease over their lifetimes (Table 2) . Their average life expectancy is 11.59 months and disease-free life expectancy is 10.42 months. If the cohort takes oral GCV preventive therapy, and if oral GCV is 49% effective, they can expect 83 symptomatic CMV cases, 50 fewer than without GCV. Life expectancy is 11.75 months, 5 days longer than without GCV preventive therapy, and disease-free life expectancy is 11.02 months, 18 days longer than without GCV. If the cohort instead has PCR testing every 3 months with oral GCV prescribed for those with positive tests, 126 symptomatic CMV cases can be expected, eight fewer than in the cohort with no prevention intervention. Life expectancy is 11.62 months, 1 day longer than with no intervention, and disease-free life expectancy is 10.51 months, 3 days longer than with no intervention. 
Sensitivity analysis
The benefits of oral GCV and PCR testing vary depending upon the effectiveness of oral GCV. Our base-case model assumes that oral GCV is 49% effective. If GCV is 100% effective, life expectancy increases 11 days with the GCV strategy and 9 days with PCR testing. If GCV is ineffective, life expectancy is not increased by the prevention strategies. 
Discussion
The CPCRA 023 study found oral GCV to be no better than placebo in preventing CMV disease in AIDS patients [6, 7] . In contrast, the Roche Cooperative Oral Ganciclovir Study found oral GCV to be 49% effective in reducing CMV disease [5] . Several differences between the studies may explain the discordant results.
The patients in the CPCRA study had less immunodeficiency and shorter follow-up during randomized drug therapy than those in the Roche study [5] . Dilated eye examinations by ophthalmologists were not required prior to entry into the CPCRA study, in contrast to the Roche study protocol, suggesting to some that patients with unrecognized retinitis on entry may explain the lack of GCV effect in the CPCRA study [5] . As mentioned above, subjects in the CPCRA study were permitted to switch to open-label oral GCV during the study [6] . Furthermore, post hoc analysis of the CPCRA study suggests that an unforeseen interaction between didanosine and oral GCV may exist, confounding the results of that study [7] . This interaction was not found in the Roche study [12] .
Our cost-effectiveness analysis found that even using the most optimistic assumption that it is 49% effective, oral GCV preventive therapy still results in very small gains in life expectancy (5 days) at a great cost; the resulting cost-effectiveness ratio, US$ 1 762 517 to extend life by 1 year, is unacceptably high and far greater than other accepted prevention interventions [20] . Oral GCV could be acceptably cost-effective as a prevention intervention (i. Modelling studies such as ours offer the advantage of comparing the importance of each variable in a complex decision. We found that the most important variables, in terms of the cost-effectiveness of these prevention interventions, are the effectiveness of GCV, the rate of developing CMV disease, the survival rate among persons with CMV disease, the cost of GCV preventive therapy, and the specificity of the CMV PCR test. Other variables, such as the GCV toxicity rate, the cost of CMV disease and GCV maintenance therapy, and the cost of the CMV PCR test, are far less important to the cost-effectiveness ratios. Decision analysis has the disadvantage, however, of exposing the uncertainty of pertinent variables. Perhaps the most uncertain of the variables is the survival of patients with CMV disease relative to persons at the same level of immunodeficiency who do not develop CMV disease. If the relative survivals are similar, few interventions will be cost effective. Since therapeutics for patients with advanced HIV disease are improving rapidly, survival rates are likely to improve as well, but the relative survival of persons with and without CMV disease may remain uncertain for some time to come.
The cost-effectiveness ratios for CMV prophylaxis compare unfavorably with those found for other opportunistic infection prevention strategies. In a similar analysis to the one reported here, we found that pneumococcal vaccination both saved money and increased life expectancy for HIV-infected people with CD4 counts above 200 × 10 6 /l and costs only US$ 2910 per year of life extended for those with CD4 counts below 200 × 10 6 /l, and that influenza vaccination costs approximately US$ 100 000 per year of life extended [21] . Castellano and Nettleman studied trimethoprim-sulfamethoxazole prophylaxis to prevent recurrent Pneumocystis carinii pneumonia and estimated its cost at approximately US$ 9000 per year of life extended [22] .
In conclusion, a cost-effective CMV disease prevention intervention has yet to be developed. Our analysis did not address other potentially effective interventions. These include the use of valaciclovir as preventive therapy [23] and plasma CMV PCR testing followed by pre-emptive treatment rather than prophylaxis [12] . If these interventions are substantially effective, safe, and inexpensive they may also be cost-effective.
